innerbuddies gut microbiome testing

Gut Microbiome & Colorectal Cancer Risk: Latest Research

Colorectal cancer risk is increasingly tied to the gut microbiome—the diverse community of microbes living in our intestines. While genetics and lifestyle matter, researchers are finding that specific patterns of gut bacteria (and the metabolic products they generate) can shape inflammation, DNA damage, immune signaling, and ultimately whether the intestinal environment becomes more or less cancer-prone.

In the latest research, “microbial signatures” associated with higher colorectal cancer risk often involve altered diversity, shifts in key bacterial groups, and changes in pathways such as bile acid metabolism, short-chain fatty acid production, and fermentation of dietary fibers. Some microbes and their metabolites may promote chronic inflammation or support tumor-friendly conditions, whereas others produce protective compounds—like butyrate—that help maintain the gut barrier and regulate cell growth.

Why this matters for prevention and early detection: the microbiome responds to diet, medications (including antibiotics and metformin), and overall gut health. As scientists refine microbiome-based biomarkers—using stool-based microbial profiles, metabolite patterns, and host responses—your gut may become a modifiable risk signal. Understanding these mechanisms helps translate emerging science into practical strategies for lowering risk and potentially identifying higher-risk individuals sooner.

Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Colorectal cancer risk

Emerging evidence links colorectal cancer risk to the gut microbiome. Dysbiosis shifts the gut ecosystem away from protective, fiber-associated taxa toward pro-carcinogenic communities, driving cancer risk through chronic inflammation, DNA damage, and disruption of the mucosal barrier, with altered bile acid metabolism shaping an epithelial environment conducive to tumor development. A growing focus is on microbial signatures and metabolite patterns—such as reduced short-chain fatty acids like butyrate—that reflect function as well as composition and may help explain individual risk beyond single organisms.

Stool-based microbiome profiling is being studied as a tool for risk stratification and earlier detection, often alongside standard screening such as FIT and colonoscopy. Diet and lifestyle remain critical, with higher fiber intake and plant-forward patterns promoting a protective microbiome and potentially increasing butyrate production, which supports barrier integrity and proper cell turnover. Because many people exhibit dysbiotic patterns rather than cancer per se, the test is not a stand-alone diagnosis but a way to refine prevention and screening decisions.

The InnerBuddies test exemplifies how microbiome data can inform colorectal cancer risk by capturing both microbial composition and functional activity. While it cannot diagnose cancer, it can help identify higher-risk individuals and guide risk-reduction strategies, including targeted dietary and lifestyle changes to boost beneficial metabolites and reduce inflammation. Symptoms such as rectal bleeding, persistent bowel changes, or iron-deficiency anemia require prompt medical evaluation, after which microbiome insights can support personalized prevention and screening discussions alongside conventional care.

  • Depletion of butyrate-producing taxa such as Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Ruminococcus bromii, Blautia spp., Anaerostipes spp., and Bifidobacterium spp leads to reduced butyrate production, weaker mucosal barrier, and impaired apoptosis of damaged cells, increasing colorectal cancer risk.
  • Enrichment of Fusobacterium nucleatum is linked to chronic colonic inflammation and pro-survival signaling in colonocytes, fostering a tumor-promoting environment.
  • Enterotoxigenic Bacteroides fragilis (CDT+) drives genotoxic stress and inflammatory responses that support carcinogenesis.
  • Colibactin-producing Escherichia coli increases DNA damage in colonocytes and disrupts normal cell cycle control.
  • Streptococcus gallolyticus is associated with colorectal neoplasia and inflammatory milieu that can aid tumor development.
  • Dysbiosis-related changes in bile acid metabolism raise secondary bile acids that promote epithelial proliferation and injury.
  • Shifts away from protective taxa and toward pro-inflammatory microbial pathways reduce short-chain fatty acid production and reinforce a pro-tumor microenvironment.
Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Other GI indications often discussed with the microbiome

The gut microbiome—made up of trillions of microbes and their metabolic products—has emerged as a key factor in colorectal cancer risk. Large epidemiologic studies and mechanistic work suggest that certain microbial communities and functions can promote colorectal tumor development, while others appear protective. Research increasingly focuses on “microbial signatures” (specific taxa, gene pathways, and metabolite patterns) that correlate with higher or lower risk, particularly in the context of inflammation, DNA damage, and mucosal barrier disruption in the colon.

Several well-supported mechanisms link dysbiosis (an imbalanced microbiome) to colorectal carcinogenesis. Some bacteria and microbial metabolic pathways produce potentially harmful compounds—such as genotoxic metabolites that can damage DNA—while others influence chronic inflammation and immune signaling, both of which can drive tumorigenesis. At the same time, reduced production of protective metabolites (notably short-chain fatty acids like butyrate) may weaken the colonic barrier, impair normal cell differentiation, and reduce apoptosis of damaged cells. Bacterial toxins and altered bile acid metabolism are also active areas of investigation, including how microbes convert primary bile acids into secondary bile acids that may affect epithelial growth and survival.

What the latest research means for prevention and early detection is shifting from “single-bug” ideas toward functional and metabolite-based approaches. Emerging evidence supports the potential for microbiome-informed risk stratification using stool-based profiling, as well as integrating microbial markers with conventional screening (e.g., FIT and colonoscopy). Diet and lifestyle—especially fiber intake, plant-rich eating patterns, and avoidance of factors that promote dysbiosis—remain the most evidence-aligned strategies to favor a microbiome pattern associated with colon health. As clinical studies mature, microbial signatures and metabolomic readouts may eventually help identify higher-risk individuals earlier and guide more personalized prevention strategies.

  • Blood in the stool (bright red or dark/tarry stool)
  • Change in bowel habits (diarrhea, constipation, or narrower stools) lasting more than a few weeks
  • Unexplained weight loss
  • Persistent abdominal discomfort or cramping
  • Iron-deficiency anemia symptoms (fatigue, weakness, shortness of breath)
  • New or worsening rectal bleeding
  • Bowel obstruction symptoms (severe constipation, bloating, abdominal pain)
Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Colorectal cancer risk

This information is relevant for people who want to understand colorectal cancer risk through the lens of the gut microbiome—especially those with personal or family history of colorectal polyps or colorectal cancer, long-standing gastrointestinal issues, or concerns about whether their diet and gut health could be influencing risk. It’s also geared toward individuals who have had abnormal results on screening tests (such as positive FIT) or who are looking for additional, stool-based ways to think about risk beyond conventional single-factor explanations.

It may be particularly relevant for anyone experiencing common warning symptoms that could signal colorectal disease and warrants medical evaluation—such as persistent rectal bleeding, blood in the stool (bright red or dark/tarry), ongoing changes in bowel habits (new diarrhea, constipation, or narrower stools lasting more than a few weeks), unexplained weight loss, persistent abdominal cramping/discomfort, or signs consistent with iron-deficiency anemia (fatigue, weakness, shortness of breath). In these situations, microbiome-focused insights should complement—never replace—prompt clinical assessment, diagnostic testing, and standard colorectal screening.

Finally, it’s useful for people who are interested in prevention and early detection strategies that emphasize gut microbial “signatures” and metabolism (for example, patterns linked to inflammation, DNA-damaging activity, bile acid transformations, or reduced protective short-chain fatty acid production like butyrate). This includes individuals looking to make evidence-aligned lifestyle changes—such as increasing fiber and plant-rich foods—to support a healthier microbial ecosystem, and those considering integrative approaches that combine stool profiling with standard screening methods (like FIT or colonoscopy) when clinically appropriate.

Colorectal cancer is common worldwide, representing a major portion of all cancer diagnoses and deaths; however, “gut microbiome dysbiosis” itself is not typically reported with a single prevalence number because it’s a spectrum and varies substantially by geography, diet, age, medications, and underlying health. Instead, studies consistently show that many people—especially those with Western dietary patterns, higher inflammatory burden, obesity, or metabolic syndrome—have microbiome patterns linked to increased colorectal cancer risk, but the exact percentage of the population carrying any specific “high-risk microbial signature” depends on the gene/taxa/metabolite definition used.

In terms of symptoms suggestive of colorectal cancer (e.g., rectal bleeding, change in bowel habits, unexplained weight loss, iron-deficiency anemia, and persistent abdominal discomfort), these are not specific to cancer and can occur with benign conditions like hemorrhoids, inflammatory bowel disease, diverticulosis, or infections—so the prevalence of symptoms in the general population is much higher than the prevalence of cancer. For example, rectal bleeding and bowel habit changes are relatively common presentations in primary care, whereas actual colorectal cancer prevalence is far lower; nonetheless, a subset of patients with persistent or progressive symptoms is found to have malignancy, which is why guidelines emphasize timely evaluation and age/risk-appropriate screening.

Screening data help approximate how frequently colorectal cancer is found in real-world populations: many countries detect colorectal neoplasia (advanced adenomas and cancers) at non-trivial rates when colonoscopy is performed, particularly in middle-aged and older adults and those with higher baseline risk (family history, prior polyps, inflammatory conditions). While stool-based microbiome profiling is still an emerging research tool, current evidence supports that risk-associated microbial functional patterns (e.g., altered bile-acid metabolism, reduced butyrate-producing capacity, and inflammation-associated pathways) may be present in a sizable fraction of the population—yet the prevalence of these specific patterns with clinically actionable thresholds remains under active study.

Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Colorectal Cancer Risk: What the Latest Research Says

The gut microbiome appears to influence colorectal cancer risk through both microbial composition and the metabolic functions they perform in the colon. Large human studies and mechanistic experiments suggest that certain microbial communities can promote tumor development, while others support protective effects. Dysbiosis can alter pathways involved in inflammation, DNA damage, mucosal barrier integrity, and epithelial cell survival—processes that are central to colorectal carcinogenesis.

Some microbiome-driven metabolites may contribute to cancer by increasing genotoxic stress and chronic inflammation. For example, microbial fermentation products can include compounds that damage DNA or disrupt normal cell regulation, and microbial signaling can intensify immune activation that sustains a pro-cancer environment. At the same time, reduced production of beneficial metabolites—especially short-chain fatty acids like butyrate—may weaken the colonic barrier, impair normal differentiation, and decrease apoptosis of damaged cells, making it easier for abnormal growths to persist.

Because microbial patterns are increasingly studied as “signatures,” stool-based profiling is being explored as a tool for risk stratification and earlier detection, often alongside standard screening such as FIT or colonoscopy. Diet and lifestyle remain the most practical ways to encourage a colon-health-associated microbiome—particularly higher fiber, more plant-rich eating patterns, and behaviors that reduce dysbiosis. Symptoms that can signal colorectal disease—such as rectal bleeding, persistent changes in bowel habits, iron-deficiency anemia, unexplained weight loss, abdominal discomfort, or signs of obstruction—should prompt medical evaluation, and microbiome insights may eventually help refine prevention strategies and identify higher-risk individuals sooner.

Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Colorectal cancer risk

  • Microbial dysbiosis shifts community structure toward pro-carcinogenic taxa that promote chronic inflammation and altered epithelial cell signaling, increasing tumor-promoting microenvironments
  • Reduced beneficial metabolites (especially short-chain fatty acids like butyrate) weakens the colonic mucosal barrier and epithelial differentiation, and can impair apoptosis of damaged cells—facilitating abnormal growth
  • Increased microbial genotoxins and carcinogenic metabolites raise DNA damage and genotoxic stress in colonocytes (e.g., via compounds that affect DNA integrity or cell-cycle regulation)
  • Microbial metabolism enhances chronic inflammation by modulating immune signaling (e.g., altered pattern-recognition receptor activation), sustaining cytokine-driven pro-cancer conditions
  • Altered bile acid metabolism changes the balance of bile acids toward more cytotoxic/ signaling-active forms that can damage the epithelium, drive proliferation, and promote tumorigenesis
  • Disruption of the mucus layer and barrier integrity allows microbial products (like LPS) to penetrate more easily, increasing inflammatory signaling and supporting tumor development
  • Microbiome-driven effects on microbial cross-feeding and metabolic pathways can create a tumor-friendly nutrient and redox environment that supports epithelial proliferation and survival

The gut microbiome can influence colorectal cancer risk by shifting its community structure and metabolic activity in ways that favor tumor growth. When dysbiosis occurs, pro-carcinogenic microbial patterns can promote chronic inflammation and alter epithelial cell signaling, creating a colonic environment that supports sustained pro-cancer immune activation and abnormal cell survival. Over time, these inflammatory and signaling changes can contribute to a microenvironment where early lesions are more likely to persist and progress.

Microbial metabolites also play a key role, both in harmful and protective directions. Some fermentation or microbial byproducts can increase genotoxic stress—raising DNA damage in colonocytes through compounds that interfere with DNA integrity or cell-cycle regulation. At the same time, reduced production of beneficial metabolites, especially short-chain fatty acids like butyrate, can weaken the mucosal barrier and impair normal epithelial differentiation and apoptosis of damaged cells. Together, increased DNA stress and decreased protective metabolite support can make abnormal growths more likely to develop and survive.

Beyond inflammation and genotoxicity, the microbiome can affect the integrity of the mucus layer and modify bile acid metabolism, both of which influence how vulnerable the epithelium is to injury. When the mucus barrier is disrupted, microbial products such as LPS can penetrate more easily, intensifying inflammatory signaling and helping maintain tumor-promoting conditions. In parallel, altered bile acid profiles can tilt toward more cytotoxic, signaling-active bile acids that drive proliferation and epithelial damage. Finally, changes in microbial cross-feeding and metabolic pathways can create a tumor-friendly nutrient and redox environment that supports epithelial proliferation and survival—further linking dysbiosis to colorectal carcinogenesis.

Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In colorectal cancer risk, research often points to dysbiosis characterized by a shift away from protective, fiber-associated communities and toward microbial patterns enriched in taxa linked to inflammation and pro-carcinogenic metabolic activity. Large observational studies and mechanistic experiments suggest that certain community structures are more likely to support persistent mucosal immune activation and altered epithelial signaling, creating an intestinal environment where early lesions can survive and progress. Stool-based “microbiome signatures” are therefore being studied as potential risk stratifiers, reflecting differences in community composition and functional capacity rather than a single organism driving disease.

Metabolic output is a major part of these characteristic patterns. Beneficial metabolites such as short-chain fatty acids—especially butyrate—are commonly reduced in dysbiotic states, which can weaken the colonic mucus layer, impair normal epithelial differentiation, and limit apoptosis of damaged cells. In parallel, some microbial fermentation byproducts and other bioactive compounds may increase genotoxic stress by interfering with DNA integrity or cell-cycle regulation, while also fueling chronic inflammation. Together, increased DNA-damaging pressure and reduced protective metabolic support can tilt the balance toward tumor persistence and growth.

Several additional functional shifts are frequently discussed alongside dysbiosis, including impaired barrier function and altered bile acid metabolism. When the mucus barrier is disrupted, inflammatory triggers such as bacterial LPS may penetrate more easily, intensifying pro-tumor immune signaling. Changes in bile acid profiles can also promote a more cytotoxic and proliferative epithelial milieu, further encouraging epithelial injury and regrowth. Finally, altered microbial cross-feeding and nutrient/redox pathways can create a more tumor-permissive environment, supporting sustained epithelial proliferation and survival—key features of colorectal carcinogenesis.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Ruminococcus bromii
  • Eubacterium rectale
  • Blautia spp.
  • Anaerostipes spp.
  • Bifidobacterium spp.


Elevated / overrepresented taxa

  • Fusobacterium nucleatum
  • Bacteroides fragilis (enterotoxigenic strains; e.g., CDT+)
  • Enterococcus faecalis
  • Escherichia coli (pathogenic/colibactin-producing strains)
  • Streptococcus gallolyticus (Group D)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and butyrate metabolism (reduction of butyrate-producing fermentation)
  • Mucus barrier maintenance via microbial fermentation metabolites and epithelial-supporting pathways
  • Chronic inflammatory signaling driven by microbial products (e.g., lipopolysaccharide/LPS translocation and inflammasome activation)
  • Bile acid transformation and secondary bile acid biosynthesis (pro-carcinogenic bile acid signaling)
  • Genotoxicity-associated pathways (DNA damage capacity via colibactin/genotoxin-associated metabolic activity)
  • Nitrosative stress and reactive nitrogen species (RNS) / oxidative stress metabolic pathways
  • Proteolytic fermentation and microbial byproduct generation (increased pro-inflammatory cytotoxic metabolites)
  • Microbial cross-feeding and nutrient/redox metabolic coupling that supports epithelial proliferation and survival


Diversity note

Colorectal cancer risk is often associated with gut microbiome dysbiosis that includes a shift in community structure and a reduction in beneficial, fiber-associated diversity. In many studies, people who develop colorectal tumors show an intestinal ecosystem with fewer taxa linked to protective functions (such as fermentation of dietary fiber into short-chain fatty acids) and a relative enrichment of microbes associated with inflammatory activity. This imbalance can reflect both loss of resilient colon-supporting species and expansion of organisms better adapted to a pro-inflammatory, nutrient-stressed colonic environment.

Beyond who is present, these diversity changes typically come with altered functional capacity. Dysbiotic communities are frequently characterized by lower production of metabolites like butyrate, a key fuel for healthy colonocytes that helps maintain the mucus barrier, supports normal epithelial differentiation, and promotes apoptosis of damaged cells. At the same time, shifts in fermentation byproducts and other microbial bioactive compounds can increase genotoxic stress and reinforce chronic inflammation, creating conditions in which early lesions are more likely to persist and progress.

Research also links colorectal cancer–associated dysbiosis to broader ecological disruption, such as impaired barrier integrity and altered microbial interactions that change how nutrients and redox compounds are processed. These functional and diversity-level shifts can promote a tumor-permissive environment by facilitating inflammatory signaling (for example, through increased exposure of the mucosa to bacterial components) and by modifying pathways involved in epithelial survival and repair. Overall, the pattern is less about one single organism and more about a less protective, functionally skewed ecosystem with reduced colon-health-associated resilience.


Buy Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail for colorectal cancer risk because they treat the gut microbiome as a uniform “health” target, when the disease-relevant biology is highly specific. Colorectal carcinogenesis is influenced by not only which microbes are present, but also what metabolic functions they perform in the colon—particularly those tied to inflammation, DNA damage, mucus/barrier integrity, and epithelial cell survival. Broad probiotic use, vague “detox” regimens, or one-size-fits-all supplements may not recreate the precise functional ecosystem that supports protective metabolites and suppresses pro-tumor pathways.

    They also fail because stool-based microbial patterns are context-dependent. Diet, baseline fiber intake, medications (especially antibiotics and acid suppression), gut transit time, and existing inflammation all shape community structure and metabolite output. Without addressing these upstream drivers, generic interventions may produce transient microbiome shifts that don’t translate into meaningful changes in colon luminal metabolites such as short-chain fatty acids (e.g., butyrate) or in functional processes like bile acid transformation and barrier-protective signaling.

    Finally, colorectal cancer risk management requires timing and risk stratification that supplements alone can’t provide. Even when a generic intervention improves general digestion or stool consistency, it may not reduce the chronic inflammatory environment or genotoxic stress that promotes lesion persistence and progression. Because symptoms and screening status matter, relying on generic gut-health products rather than tailored dietary patterns, evidence-aligned prevention strategies (e.g., FIT/colonoscopy when indicated), and individualized risk assessment can leave the underlying cancer-driving mechanisms largely unaddressed.

  • Common mistakes

    • Treating colorectal cancer risk microbiome biology as a generic “gut health” problem, rather than targeting dysbiosis-related functions (mucus/barrier support, reduced inflammation, lower genotoxic metabolic pressure, restored epithelial protective signaling).
    • Using broad probiotic blends or single-strain interventions without confirming colon-relevant engraftment/function (and without checking whether they actually increase protective metabolites like butyrate or reduce pro-inflammatory/toxic metabolic outputs).
    • Assuming stool-based microbiome signatures are universal, instead of recognizing strong context dependence from diet (especially baseline fiber), medications (antibiotics/PPIs), gut transit time, and existing inflammation.
    • Overlooking the metabolic layer and focusing only on “more diversity” or symptom relief, even though colorectal risk is driven by functional capacity (SCFA production, bile acid transformation, redox/nutrient cross-feeding) more than by presence/absence of specific taxa.
    • Neglecting bile acid metabolism and barrier/mucus integrity as actionable mechanisms, leading to interventions that may not shift bile acid profiles, LPS exposure, or epithelial injury/proliferation dynamics.
    • Promoting “detox” or vague cleansing/anti-bloat regimens that can be non-specific, disruptive, or poorly aligned with long-term ecosystem rebuilding, resulting in transient microbiome changes that don’t translate into meaningful metabolite or immune signaling improvements.
    • Ignoring timing and risk stratification—relying on supplements or microbiome changes as a substitute for evidence-based prevention (e.g., appropriate FIT/colonoscopy) and individualized risk assessment.
    • Failing to address upstream drivers (dietary fiber quality/amount, weight/metabolic factors, medication optimization) that determine whether the microbiome can produce protective outputs consistently rather than temporarily.

What to do

  • General support strategies

    For colorectal cancer risk, the gut microbiome is thought to influence carcinogenesis by shaping inflammation, DNA damage, mucosal barrier function, and epithelial cell survival. A common theme in research is that dysbiosis—an imbalanced community—can promote pro-cancer signaling, while a more diverse, resilient microbiome supports protective pathways. Strategies that encourage a healthier microbial ecosystem therefore aim to reduce harmful metabolic outputs and strengthen the colon environment where immune and epithelial processes are tightly regulated.

    Diet is the most practical lever to support colon-associated microbial health. Emphasizing high-fiber, plant-rich eating patterns (including beans, lentils, whole grains, fruits, and vegetables) helps beneficial microbes thrive and can increase production of short-chain fatty acids such as butyrate. Butyrate supports epithelial barrier integrity, helps regulate differentiation, and may reduce the persistence of damaged cells. In contrast, diets low in fiber and high in processed foods may reduce beneficial metabolite production and favor microbial functions linked to inflammation or genotoxic stress.

    Because microbiome-driven risk signals are increasingly studied through stool-based “signatures,” they may complement standard prevention tools like FIT or colonoscopy as research advances. Still, supportive lifestyle choices—staying physically active, maintaining a healthy weight, limiting alcohol, and avoiding tobacco—can indirectly support a more favorable microbiome. Importantly, any symptoms that could suggest colorectal disease (such as rectal bleeding, ongoing changes in bowel habits, iron-deficiency anemia, unexplained weight loss, persistent abdominal discomfort, or signs of obstruction) warrant prompt medical evaluation rather than relying on microbiome insights alone.

  • Lifestyle recommendations

    • Eat a high-fiber, plant-forward diet (more fruits, vegetables, legumes, whole grains) to support beneficial gut microbes and short-chain fatty acid production (e.g., butyrate).
    • Reduce intake of ultra-processed foods and excess red/processed meats, which can promote dysbiosis and harmful microbial metabolic byproducts.
    • Maintain a healthy body weight through regular physical activity, as obesity is linked to higher colorectal cancer risk and microbiome disruption.
    • Avoid smoking and limit alcohol, both of which can worsen gut microbial balance and increase inflammation.
    • Prioritize regular bowel habits and colorectal health behaviors (e.g., stay hydrated, consider fiber gradually if needed) to support mucosal integrity.
    • Follow recommended colorectal cancer screening (e.g., FIT and/or colonoscopy) for your age/risk level, and seek medical evaluation for symptoms like rectal bleeding, persistent bowel habit changes, iron-deficiency anemia, unexplained weight loss, or persistent abdominal discomfort.

  • Nutrition recommendations

    • Increase daily fiber to ~25–38 g/day from a plant-forward diet (beans/lentils, whole grains like oats and brown rice, fruits, vegetables) to support beneficial microbial communities and butyrate production.
    • Prioritize prebiotic foods (garlic, onions, leeks, asparagus, bananas, oats, barley, chicory root/inulin when tolerated) to promote growth of fiber-fermenting, protective gut bacteria.
    • Include probiotic-rich foods regularly (e.g., yogurt with live cultures, kefir, fermented vegetables like sauerkraut/kimchi, tempeh) as appropriate for tolerance, aiming to improve microbial balance.
    • Limit ultra-processed foods, refined sugars, and excess red/processed meats, which are associated with higher colorectal cancer risk and can worsen dysbiosis and inflammatory signaling.
    • Support a healthy fat profile by choosing more unsaturated fats (olive oil, nuts, seeds, avocado, fatty fish) and reduce high saturated fat intake, which can influence bile acids and gut microbial metabolism.
    • Ensure adequate calcium and vitamin D from food or supplementation when needed, as evidence suggests they may help protect against colorectal tumor development and modulate microbial-related pathways.
    • If you drink alcohol, keep it minimal (or avoid), since alcohol can disrupt gut microbial ecology and increase inflammatory and genotoxic stress in the colon.

  • Supplement considerations

    For colorectal cancer risk, supplement strategies are generally focused on supporting a colon-friendly gut ecosystem rather than targeting cancer directly. The microbiome can influence carcinogenesis through effects on inflammation, DNA damage, mucosal barrier integrity, and epithelial cell survival; dysbiosis and low production of protective metabolites may tilt the balance toward tumor-promoting conditions. Supplements that increase dietary-like fermentation signals (especially those that can support beneficial short-chain fatty acid pathways such as butyrate) may help strengthen barrier function and reduce chronic inflammatory tone, which are key processes linked to colorectal tumor development.

    Probiotic and prebiotic approaches are often considered, but the most appropriate choice depends on baseline diet, existing microbiome patterns, and tolerance. Prebiotic fibers (or fiber-like compounds) can promote growth of protective microbes, while specific probiotic strains may help modulate immune activity and strengthen gut barrier signaling. However, effects can be strain- and dose-dependent, and not everyone responds the same way—especially in people with inflammatory bowel disease, prior bowel surgery, or active symptoms. Because colorectal cancer risk is serious, supplements should be viewed as adjuncts to evidence-based screening (FIT, colonoscopy) and overall risk reduction, not replacements.

    Given the role of microbial metabolites and bile acid signaling in colon health, some supplements aimed at normalizing gut function—such as those supporting SCFA production or influencing bile acid composition—may be explored in consultation with a clinician. Antioxidant-oriented supplements have also been discussed because oxidative stress and genotoxic stress can contribute to carcinogenesis, but they are not a guaranteed prevention tool and may interfere with certain cancer therapies if used during treatment. If there are red-flag symptoms (rectal bleeding, persistent bowel habit changes, iron-deficiency anemia, unexplained weight loss, persistent abdominal discomfort), medical evaluation should come first so that appropriate diagnostics can be performed before considering any gut-focused supplements.

  • Retesting / monitoring note

    For colorectal cancer risk, any microbiome-based assessment (such as stool profiling used alongside FIT or other screening) is typically most useful when repeated to confirm that observed microbial signatures are persistent rather than temporary. Because gut communities can shift with recent diet changes, infections, antibiotics, travel, or gut inflammation, retesting is often recommended after a stabilization period—commonly several weeks to a few months—so results better reflect longer-term patterns associated with dysbiosis or colon-health–related metabolic function.

    If the initial test suggests higher-risk microbial patterns or reduced protective functions (for example, lower short-chain fatty acid–related signatures linked to barrier support), clinicians may recommend retesting after implementing actionable lifestyle changes, such as increasing fiber and plant diversity, reducing ultra-processed foods, and avoiding unnecessary antibiotics. The goal of retesting in this context is to determine whether the microbiome signature moves toward a more protective configuration, which may correlate with improved colonic barrier integrity and a lower inflammatory, DNA-damage–prone environment.

    Retesting is also considered when symptoms or screening outcomes raise concern—such as rectal bleeding, persistent bowel habit changes, iron-deficiency anemia, unexplained weight loss, or persistent abdominal discomfort. In these situations, microbiome results should not replace standard medical evaluation; instead, follow-up testing may be used to support risk stratification while the appropriate diagnostic workup (often colonoscopy) proceeds. Ongoing monitoring timelines are best individualized based on age, family history, prior polyp findings, and the screening strategy already in place.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters for colorectal cancer risk because it can reveal how microbial communities—and the metabolic activities they drive in the colon—may influence the biological pathways that underlie carcinogenesis. Research suggests that certain dysbiotic patterns are associated with higher inflammation, increased genotoxic stress, impaired mucosal barrier function, and altered epithelial cell signaling—processes that can promote tumor development. By capturing both “who is there” and “what they’re doing,” microbiome profiling may help clarify an individual’s risk landscape beyond conventional factors alone.

    Stool-based microbiome signatures are also being studied as potential tools for risk stratification and earlier detection when combined with standard screening approaches like FIT or colonoscopy. While microbiome data typically isn’t a standalone diagnosis, it may contribute to identifying people who are more likely to have colon environments that favor harmful metabolic byproducts or reduced production of protective compounds such as short-chain fatty acids (especially butyrate). Those shifts can affect DNA repair capacity, immune regulation, and the maintenance of normal epithelial cell differentiation and apoptosis.

    Finally, microbiome testing may be useful because it can guide prevention strategies that are practical and modifiable—particularly diet quality (higher fiber and plant-rich patterns), lifestyle factors, and interventions aimed at improving gut ecosystem balance. For individuals with symptoms that warrant evaluation—such as rectal bleeding, persistent bowel habit changes, iron-deficiency anemia, unexplained weight loss, or abdominal discomfort—microbiome insights may eventually help refine how clinicians assess risk and tailor follow-up, while standard medical workup remains essential.

  • How InnerBuddies helps

    The InnerBuddies test can help with colorectal cancer risk by profiling the gut microbiome “signature” that may be associated with dysbiosis-driven carcinogenesis. Because different microbial communities and their metabolic activities can influence key colon processes—such as chronic inflammation, DNA-damaging stress, mucosal barrier integrity, and epithelial cell survival—the test provides insight into the microbial ecology that may shape a more protective or higher-risk colon environment. In particular, it can reflect patterns linked to unfavorable metabolite production and reduced generation of beneficial compounds like short-chain fatty acids (including butyrate), which are important for gut barrier function and normal epithelial regulation.

    While microbiome testing cannot diagnose cancer on its own, InnerBuddies can be used to complement conventional screening (such as FIT or colonoscopy) and standard risk assessment. By capturing both the types of microbes present and how the ecosystem appears to be functioning, the results may support earlier identification of individuals who show microbiome features associated with higher inflammation and altered epithelial signaling. This can be helpful for risk stratification and for discussions with clinicians about how aggressively to pursue screening or follow-up based on overall clinical context.

    InnerBuddies can also support prevention by translating microbiome patterns into actionable targets—most importantly, diet and lifestyle strategies that promote a healthier gut ecosystem. Because fiber-rich, plant-forward dietary patterns and other behaviors that reduce dysbiosis are among the most practical ways to shift the microbiome toward a more protective metabolic profile, the test can help guide personalized efforts to strengthen colon health over time. If you have symptoms that warrant evaluation (for example, rectal bleeding, persistent bowel changes, iron-deficiency anemia, unexplained weight loss, abdominal discomfort, or obstruction signs), the microbiome results should be used to inform your next steps alongside prompt medical care.

Medical Evidence

  • Scientific evidence level

    2 [weak; emerging but inconsistent—mostly association/biologic plausibility with limited causal and clinical utility evidence]

  • Clinical relevance note

    At present, gut microbiome measures are best viewed as hypothesis-generating and supportive of biologic mechanisms rather than as validated tools for CRC risk management. The human evidence base supports the idea that dysbiosis correlates with CRC and sometimes with later risk, but the field lacks a consistent, externally validated microbial signature that is reproducible across populations and robust to confounding (diet, medications such as metformin/PPIs/antibiotics, BMI, smoking, collection/processing variables) and to reverse causality from occult/preclinical disease.

    Clinically, this means that routine microbiome testing for CRC prevention or risk stratification is not supported by high-quality evidence. Even where statistical associations exist, they do not yet translate into actionable interventions with demonstrated reductions in CRC incidence or clear guidance on who would benefit from microbiome-modulating strategies. The most credible current use is in research settings (e.g., improving mechanistic understanding and identifying candidates for prevention trials), while standard CRC prevention and screening should remain the primary evidence-based approach.

Title Journal Year Link
Microbial signatures predict future colorectal cancer in a prospective cohort study Gut 2021 View →
Microbiome diversity and colorectal cancer risk: a prospective analysis Journal of the National Cancer Institute 2020 View →
Gut microbiome composition and colorectal cancer: a large-scale cohort study Nature Medicine 2019 View →
Association between gut microbiome and colorectal cancer: a meta-analysis of case-control studies Cancer Medicine 2019 View →
Gut microbiome and colorectal cancer risk: a systematic review and meta-analysis of cohort studies Clinical Gastroenterology and Hepatology 2019 View →

Frequently Asked Questions

    ¿Qué es el microbioma intestinal y cómo se relaciona con el riesgo de cáncer colorrectal?
    El microbioma intestinal es la comunidad de microorganismos en el intestino y sus productos metabólicos. La investigación muestra asociaciones entre ciertos patrones microbianos y el riesgo de cáncer colorrectal, pero es un área en evolución y no es una prueba diagnóstica.
    ¿Qué microbios se asocian con mayor riesgo y cuáles son protectores?
    Protectoras: taxa ligadas a la fibra como Faecalibacterium prausnitzii, Roseburia, Ruminococcus bromii, Eubacterium rectale, Blautia, Anaerostipes y Bifidobacterium. De mayor riesgo: Fusobacterium nucleatum, Bacteroides fragilis enterotoxigénico, Enterococcus faecalis, ciertas cepas de E. coli y Streptococcus gallolyticus. Los resultados varían entre estudios.
    ¿Qué mecanismos conectan la disbiosis con el cáncer colorrectal?
    La disbiosis puede promover inflamación crónica, daño al ADN, alteración de la barrera mucosa y señales epiteliales alteradas. Algunos metabolitos pueden dañar el ADN; la producción reducida de butirato puede debilitar la barrera.
    ¿Puede una prueba del microbioma predecir el riesgo de cáncer colorrectal?
    Actualmente no se usa una prueba única para predecir cáncer. Es un área de investigación y no es una herramienta diagnóstica.
    ¿Se recomienda la prueba del microbioma como parte del cribado?
    No es parte estándar del cribado; las decisiones deben hacerse con un médico y junto a los métodos de cribado ya establecidos.
    ¿Cómo influye la dieta en el microbioma y el riesgo de cáncer?
    Las dietas ricas en fibra y con muchos vegetales se han asociado en la investigación con un perfil microbiológico más saludable.
    ¿Qué cambios de estilo de vida pueden apoyar un microbioma más saludable?
    En general, seguir una dieta rica en fibra y basada en plantas y reducir factores que favorecen la disbiosis puede ayudar. Habla con un médico para recomendaciones personalizadas.
    ¿Cómo complementa la información del microbioma al cribado estándar como FIT o colonoscopia?
    La información del microbioma puede aportar contexto adicional, pero no reemplaza el cribado establecido.
    ¿Cuáles son los síntomas comunes del cáncer colorrectal y cuándo consultar?
    Sangre en las heces, cambios persistentes en los hábitos intestinales, pérdida de peso inexplicada, anemia por deficiencia de hierro y dolor abdominal requieren evaluación médica.
    ¿Qué es el butirato y por qué es importante?
    El butirato es un ácido graso de cadena corta que apoya la mucosa del colon; niveles bajos se han asociado con una barrera intestinal menos robusta en algunas investigaciones.
    ¿Existen pruebas clínicas del microbioma utilizadas hoy?
    Algunos laboratorios ofrecen perfiles del microbioma, pero no son herramientas estándar para el diagnóstico de cáncer y se usan principalmente con fines exploratorios.
    ¿Cuáles son las limitaciones de la investigación actual sobre el microbioma?
    Los resultados pueden variar según la población y el método; aún no hay umbrales clínicos establecidos ni usos diagnósticos definitivos.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -